Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese Middle Class Shuns Western Drugs In Favor Of Traditional Medicine (China)

This article was originally published in PharmAsia News

Executive Summary

Western drug makers are finding China's middle class a tough sell even though Chinese in that group are fans of U.S. cars and Starbucks. They still confine their drug spending to an average $10 a year, compared with the $900 American average. The Chinese middle class is as large as the entire U.S. population, but drug makers who have invested more than $1 billion in China the past 15 years have had little success in cracking the Chinese preference for traditional local medicine based on ingredients in plants. China also prohibits direct-to-consumer advertising for prescription drugs. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC065924

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel